New study examines Real-World side effects of lung cancer therapies

NCT ID NCT07215962

Ongoing Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 300 patients with advanced non-small cell lung cancer whose tumors have low PD-L1 levels (below 1%). Researchers will look at side effects and healthcare use for different first-line treatments, including combinations of immunotherapy drugs like nivolumab and ipilimumab with or without chemotherapy. The goal is to understand how these treatments work in everyday practice, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab, ipilimumab, and other immunotherapy drugs combined with chemotherapy
What this could lead to: If successful, this could help doctors choose safer and more effective first-line treatments for advanced lung cancer patients with low PD-L1 levels.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Florida Cancer Specialists & Research Institute

Fleming Island, Florida, 32003, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.